CONTROLLED SUBSTANCES FOR TREATMENT

OF EPILEPSY OR SEIZURE DISORDER

House Bill 6288 as introduced

Sponsor:  Rep. Hank Vaupel

Committee:  Health Policy

Complete to 11-27-18

SUMMARY:

House Bill 6288 would amend section 7303a of the Public Health Code, which pertains to the prescribing or dispensing of controlled substances.

Currently, this section requires a licensed prescriber to obtain and review a patient’s Michigan Automated Prescription System (MAPS) report before prescribing more than a three-day supply of a Schedule 2 through 5 controlled substance to the patient. (This requirement was added by Public Act 248 of 2017.[1])

The bill would exempt controlled substances prescribed for the treatment of epilepsy or seizure disorder from the MAPS requirement if the controlled substance were approved by the U.S. Food and Drug Administration for the treatment or therapy of a patient with epilepsy or seizure disorder.

The bill would define epilepsy or seizure disorder to include any of the following:

·         A neurological disease diagnosed when an individual has recurrent and unprovoked seizures or is at high risk of seizures.

·         A diagnosed epilepsy syndrome.

·         A condition of the brain causing seizure activity, regardless of onset origin.

The bill would take effect 90 days after enactment.

MCL 333.7303a

FISCAL IMPACT:

House Bill 6288 would not have an impact on expenditures or revenues of any unit of state or local government. The bill would add FDA-approved epilepsy drugs used for the treatment of epilepsy to a list of exemptions from the requirement regarding prescribers obtaining MAPS reports, which would not result in any fiscal impact.

                                                                                         Legislative Analyst:   Dana Adams

                                                                                                 Fiscal Analyst:   Marcus Coffin

■ This analysis was prepared by nonpartisan House Fiscal Agency staff for use by House members in their deliberations, and does not constitute an official statement of legislative intent.

---